Eltrombopag in pediatric chronic and refractory ITP: data from a retrospective multicenter study from Lebanon.
Bleeding disorders
Chronic and refractory ITP, immune thrombocytopenia
Eltrombopag
Pediatric
Retrospective study
Journal
Annals of hematology
ISSN: 1432-0584
Titre abrégé: Ann Hematol
Pays: Germany
ID NLM: 9107334
Informations de publication
Date de publication:
May 2022
May 2022
Historique:
received:
16
06
2021
accepted:
18
02
2022
pubmed:
13
3
2022
medline:
13
4
2022
entrez:
12
3
2022
Statut:
ppublish
Résumé
About 20% to 30% of pediatric patients with immune thrombocytopenia (ITP) develop chronic or refractory disease lasting 12 months or more that can be challenging to treat. Eltrombopag is being used after failure of previous lines of therapy with good results at tertiary healthcare centers in Lebanon, a developing country with available multidisciplinary treatment modalities. This is a retrospective multicenter observational study that analyzed data on pediatric patients with chronic or refractory ITP who were given eltrombopag as second- or third-line therapy in 6 large referral hospitals in Beirut (country capital located in mid Lebanon), South, North, and Mount Lebanon between October 2016 and May 2020. The primary end point of the study was a proportion of patients achieving platelet counts of ≥ 50 × 10
Identifiants
pubmed: 35278100
doi: 10.1007/s00277-022-04804-z
pii: 10.1007/s00277-022-04804-z
doi:
Substances chimiques
Benzoates
0
Hydrazines
0
Pyrazoles
0
eltrombopag
S56D65XJ9G
Types de publication
Journal Article
Multicenter Study
Observational Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
991-997Subventions
Organisme : novartis
ID : 1245578
Informations de copyright
© 2022. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.
Références
Kuhne T, Imbach P, Bolton-Maggs PHB et al (2001) For the International Childhood ITP Study Group. Newly diagnosed idiopathic thrombocytopenic purpura in childhood: an observational study. Lancet 358:2122–2155
doi: 10.1016/S0140-6736(01)07219-1
Al-Samkari H, Kuter DJ (2019) Optimal use of thrombopoietin receptor agonists in immune thrombocytopenia. Ther Adv Hematol 10:2040620719841735. https://doi.org/10.1177/2040620719841735
Neunert C, Despotovic J, Haley K et al (2016) Pediatric ITP Consortium of North America (ICON). Thrombopoietin receptor agonist use in children: data from the Pediatric ITP Consortium of North America ICON2 Study. Pediatr Blood Cancer 63(8):1407–13
doi: 10.1002/pbc.26003
Cserhati I, Kelemen E (1958) Acute prolonged thrombocytosis in mice induced by thrombocythaemic sera; a possible human thrombopoietin; a preliminary communication. Acta Med Acad Sci Hung 11(4):473–475
pubmed: 13594249
Bartley TD, Bogenberger J, Hunt P et al (1994) Identification and cloning of a megakaryocyte growth and development factor that is a ligand for the cytokine receptor Mpl. Cell 77(7):1117–1124
doi: 10.1016/0092-8674(94)90450-2
de Sauvage FJ, Hass PE, Spencer SD et al (1994) Stimulation of megakaryocytopoiesis and thrombopoiesis by the c-Mpl ligand. Nature 369(6481):533–538
doi: 10.1038/369533a0
Kuter DJ, Beeler DL, Rosenberg RD (1994) The purification of megapoietin: a physiological regulator of megakaryocyte growth and platelet production. Proc Natl Acad Sci USA 91(23):11104–11108
doi: 10.1073/pnas.91.23.11104
Foster DC, Sprecher CA, Grant FJ et al (1994) Human thrombopoietin: gene structure, cDNA sequence, expression, and chromosomal localization. Proc Natl Acad Sci USA 91(26):13023–13027
doi: 10.1073/pnas.91.26.13023
Lok S, Kaushansky K, Holly RD et al (1994) Cloning and expression of murine thrombopoietin cDNA and stimulation of platelet production in vivo. Nature 369(6481):565–568
doi: 10.1038/369565a0
Basser RL, Rasko JE, Clarke K et al (1996) Thrombopoietic effects of pegylated recombinant human megakaryocyte growth and development factor (PEGrHuMGDF) in patients with advanced cancer. Lancet 348(9037):1279–1281
doi: 10.1016/S0140-6736(96)04471-6
Archimbaud E, Ottmann OG, Yin JA et al (1999) A randomized, double-blind, placebo-controlled study with pegylated recombinant human megakaryocyte growth and development factor (PEG-rHuMGDF) as an adjunct to chemotherapy for adults with de novo acute myeloid leukemia. Blood 94(11):3694–3701
doi: 10.1182/blood.V94.11.3694
Kuter DJ, Goodnough LT, Romo J et al (2001) Thrombopoietin therapy increases platelet yields in healthy platelet donors. Blood 98(5):1339–1345
doi: 10.1182/blood.V98.5.1339
Schiffer CA, Miller K, Larson RA et al (2000) A double-blind, placebo-controlled trial of pegylated recombinant human megakaryocyte growth and development factor as an adjunct to induction and consolidation therapy for patients with acute myeloid leukemia. Blood 95(8):2530–2535
doi: 10.1182/blood.V95.8.2530
Bussel JB, de Miguel PG, Despotovic JM et al (2015) Eltrombopag for the treatment of children with persistent and chronic immune thrombocytopenia (PETIT): a randomised, multicentre, placebo-controlled study. Lancet Haematol 2(8):e315–e325
doi: 10.1016/S2352-3026(15)00114-3
Grainger JD, Locatelli F, Chotsampancharoen T et al (2015) Eltrombopag for children with chronic immune thrombocytopenia (PETIT2): a randomised, multicentre, placebo-controlled trial. Lancet 386(10004):1649–1658
doi: 10.1016/S0140-6736(15)61107-2
Kim TO, Despotovic J, Lambert MP (2018) Eltrombopag for use in children with immune thrombocytopenia. Blood Adv 2(4):454–461
doi: 10.1182/bloodadvances.2017010660
Rodeghiero F, Stasi R, Gernsheimer T et al (2009) Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children: report from an international working group. Blood 113(11):2386–2393
doi: 10.1182/blood-2008-07-162503
González-López TJ, Pascual C, Álvarez-Román MT et al (2015) Successful discontinuation of eltrombopag after complete remission in patients with primary immune thrombocytopenia. Am J Hematol 90(3):E40–E43
doi: 10.1002/ajh.23900
Giordano P, Lassandro G, Barone A et al (2020) Use of eltrombopag in children with chronic immune thrombocytopenia (ITP): a real life retrospective multicenter experience of the Italian Association of Pediatric Hematology and Oncology (AIEOP). Front Med (Lausanne) 7:66. https://doi.org/10.3389/fmed.2020.00066 (eCollection 2020)
doi: 10.3389/fmed.2020.00066